Abzena emphasizes early, integrated immunogenicity risk assessment in drug development to identify and mitigate anti-drug immune responses. Using tools like iTope-AI, TCED™, and the EpiScreen® 2.0 platform, Abzena combines in silico prediction with ex vivo validation to map T cell epitopes and assess CD4+/CD8+ activation and cytokine release. This approach improves candidate selection, supports regulatory compliance, and enables safer biologic therapies. Tailored strategies address challenges for antibodies, ADCs, and gene/cell therapies. Case studies with TGN1412, natalizumab, and Vatreptacog Alfa show the value of predictive testing in preventing adverse immune reactions.

Join for free to read